Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial
- PMID: 16325694
- DOI: 10.1016/S0140-6736(05)67704-5
Bypass versus angioplasty in severe ischaemia of the leg (BASIL): multicentre, randomised controlled trial
Abstract
Background: The treatment of rest pain, ulceration, and gangrene of the leg (severe limb ischaemia) remains controversial. We instigated the BASIL trial to compare the outcome of bypass surgery and balloon angioplasty in such patients.
Methods: We randomly assigned 452 patients, who presented to 27 UK hospitals with severe limb ischaemia due to infra-inguinal disease, to receive a surgery-first (n=228) or an angioplasty-first (n=224) strategy. The primary endpoint was amputation (of trial leg) free survival. Analysis was by intention to treat. The BASIL trial is registered with the National Research Register (NRR) and as an International Standard Randomised Controlled Trial, number ISRCTN45398889.
Findings: The trial ran for 5.5 years, and follow-up finished when patients reached an endpoint (amputation of trial leg above the ankle or death). Seven individuals were lost to follow-up after randomisation (three assigned angioplasty, two surgery); of these, three were lost (one angioplasty, two surgery) during the first year of follow-up. 195 (86%) of 228 patients assigned to bypass surgery and 216 (96%) of 224 to balloon angioplasty underwent an attempt at their allocated intervention at a median (IQR) of 6 (3-16) and 6 (2-20) days after randomisation, respectively. At the end of follow-up, 248 (55%) patients were alive without amputation (of trial leg), 38 (8%) alive with amputation, 36 (8%) dead after amputation, and 130 (29%) dead without amputation. After 6 months, the two strategies did not differ significantly in amputation-free survival (48 vs 60 patients; unadjusted hazard ratio 1.07, 95% CI 0.72-1.6; adjusted hazard ratio 0.73, 0.49-1.07). We saw no difference in health-related quality of life between the two strategies, but for the first year the hospital costs associated with a surgery-first strategy were about one third higher than those with an angioplasty-first strategy.
Interpretation: In patients presenting with severe limb ischaemia due to infra-inguinal disease and who are suitable for surgery and angioplasty, a bypass-surgery-first and a balloon-angioplasty-first strategy are associated with broadly similar outcomes in terms of amputation-free survival, and in the short-term, surgery is more expensive than angioplasty.
Comment in
-
Life and limb: bypass versus angioplasty in the ischaemic limb.Lancet. 2005 Dec 3;366(9501):1905-6. doi: 10.1016/S0140-6736(05)67705-7. Lancet. 2005. PMID: 16325681 No abstract available.
-
Bypass surgery and balloon angioplasty did not differ for amputation-free survival in severe limb ischemia.ACP J Club. 2006 May-Jun;144(3):69. ACP J Club. 2006. PMID: 16646613 No abstract available.
-
Bypass versus angioplasty in severe ischaemia of the leg.Lancet. 2006 Jun 3;367(9525):1814; author reply 1815-6. doi: 10.1016/S0140-6736(06)68794-1. Lancet. 2006. PMID: 16753476 No abstract available.
-
Bypass versus angioplasty in severe ischaemia of the leg.Lancet. 2006 Jun 3;367(9525):1815; author reply 1815-6. doi: 10.1016/S0140-6736(06)68795-3. Lancet. 2006. PMID: 16753478 No abstract available.
Similar articles
-
Vein bypass first vs. best endovascular treatment first revascularisation strategy for chronic limb-threatening ischaemia due to infra-popliteal disease: the BASIL-2 RCT.Health Technol Assess. 2024 Oct;28(65):1-72. doi: 10.3310/YTFV4524. Health Technol Assess. 2024. PMID: 39397484 Free PMC article. Clinical Trial.
-
Multicentre randomised controlled trial of the clinical and cost-effectiveness of a bypass-surgery-first versus a balloon-angioplasty-first revascularisation strategy for severe limb ischaemia due to infrainguinal disease. The Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) trial.Health Technol Assess. 2010 Mar;14(14):1-210, iii-iv. doi: 10.3310/hta14140. Health Technol Assess. 2010. PMID: 20307380 Clinical Trial.
-
A vein bypass first versus a best endovascular treatment first revascularisation strategy for patients with chronic limb threatening ischaemia who required an infra-popliteal, with or without an additional more proximal infra-inguinal revascularisation procedure to restore limb perfusion (BASIL-2): an open-label, randomised, multicentre, phase 3 trial.Lancet. 2023 May 27;401(10390):1798-1809. doi: 10.1016/S0140-6736(23)00462-2. Epub 2023 Apr 25. Lancet. 2023. PMID: 37116524 Clinical Trial.
-
Bypass versus Angioplasty in Severe Ischaemia of the Leg (BASIL) and the (hoped for) dawn of evidence-based treatment for advanced limb ischemia.J Vasc Surg. 2010 May;51(5 Suppl):69S-75S. doi: 10.1016/j.jvs.2010.02.001. J Vasc Surg. 2010. PMID: 20435263 Review.
-
Bypass surgery for chronic lower limb ischaemia.Cochrane Database Syst Rev. 2017 Apr 3;4(4):CD002000. doi: 10.1002/14651858.CD002000.pub3. Cochrane Database Syst Rev. 2017. PMID: 28368090 Free PMC article. Review.
Cited by
-
Brazilian Society of Angiology and Vascular Surgery guidelines on peripheral artery disease.J Vasc Bras. 2024 Oct 28;23:e20230059. doi: 10.1590/1677-5449.202300592. eCollection 2024. J Vasc Bras. 2024. PMID: 39493832 Free PMC article.
-
Directional Atherectomy for Critical Lower Limb Ischemia: A Retrospective Observational Study.Cureus. 2024 Oct 4;16(10):e70840. doi: 10.7759/cureus.70840. eCollection 2024 Oct. Cureus. 2024. PMID: 39493072 Free PMC article.
-
Prognostic Nutritional Index as a New Prediction Tool for All-Cause Mortality in Patients with Chronic Limb-Threatening Ischemia Undergoing Endovascular Therapy.Sisli Etfal Hastan Tip Bul. 2024 Sep 30;58(3):346-353. doi: 10.14744/SEMB.2024.70094. eCollection 2024. Sisli Etfal Hastan Tip Bul. 2024. PMID: 39411041 Free PMC article.
-
Vein bypass first vs. best endovascular treatment first revascularisation strategy for chronic limb-threatening ischaemia due to infra-popliteal disease: the BASIL-2 RCT.Health Technol Assess. 2024 Oct;28(65):1-72. doi: 10.3310/YTFV4524. Health Technol Assess. 2024. PMID: 39397484 Free PMC article. Clinical Trial.
-
miRNA in the Diagnosis and Treatment of Critical Limb Ischemia.Biomedicines. 2024 Sep 4;12(9):2026. doi: 10.3390/biomedicines12092026. Biomedicines. 2024. PMID: 39335540 Free PMC article.
Publication types
MeSH terms
Associated data
Grants and funding
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous
